NASDAQ:ACET Adicet Bio Q2 2026 Earnings Report $8.95 -0.23 (-2.54%) As of 03:23 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Adicet Bio EPS ResultsActual EPS-$1.99Consensus EPS -$1.69Beat/MissMissed by -$0.30One Year Ago EPSN/AAdicet Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAdicet Bio Announcement DetailsQuarterQ2 2026Date8/5/2026TimeAfter Market ClosesConference Call DateWednesday, August 5, 2026Conference Call Time4:00PM ETUpcoming EarningsAdicet Bio's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Adicet Bio Earnings HeadlinesHC Wainwright Reiterates "Buy" Rating for Adicet Bio (NASDAQ:ACET)September 20 at 1:18 AM | americanbankingnews.comAdicet Bio (ACET): The Countdown To Prula-cel DataSeptember 15, 2026 | rttnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.September 21 at 1:00 AM | Banyan Hill Publishing (Ad)Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without ...September 1, 2026 | finance.yahoo.comAdicet Bio Announces FDA Clearance of IND Application for ADI-212August 27, 2026 | finance.yahoo.comAdicet Bio Gets FDA Clearance for IND for ADI-212 in prostate cancerAugust 27, 2026 | finance.yahoo.comSee More Adicet Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adicet Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adicet Bio and other key companies, straight to your email. Email Address About Adicet BioAdicet Bio (NASDAQ:ACET) is a clinical-stage biotechnology company developing allogeneic T-cell therapies for the treatment of cancer. Its platform is based on gamma delta T cells, a type of immune cell that may be engineered to recognize and attack tumor cells while potentially offering advantages associated with off-the-shelf cell therapies. The company’s pipeline has included investigational CAR T-cell products designed to target specific cancer antigens, including ADI-001, an anti-CD19 therapy developed for B-cell malignancies. Adicet’s research also focuses on applying its cell-engineering and manufacturing technologies to develop additional treatments for hematologic cancers and solid tumors. Founded in 2014, Adicet Bio is headquartered in the United States and conducts research and development activities aimed at advancing allogeneic, or donor-derived, cell therapies. Its products remain investigational and are subject to clinical testing and regulatory review.View Adicet Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
